Tag Archives: Mark Smith

API to buy out Sigma

Australian Pharmaceutical Industries Limited (API) acquires 100 per cent of the shares in Sigma, via a scheme of arrangement (scheme). Under that proposal Sigma’s shareholders would receive 0.31 API shares and $0.23 cash for each Sigma share. Based on the terms of the API proposal and the API share price …

Read More »